3-溴-4-氟苯甲酸乙酯 | 23233-33-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-4-氟苯甲酸乙酯
• 英文名称: ethyl 3-bromo-4-fluorobenzoate
• CAS: 23233-33-2
• 化学式: C₉H₈BrFO₂
• 分子量: 247.064
• InChiKey: FDVAAQDTTZNHKG-UHFFFAOYSA-N

物化性质

• 沸点：
  262.6±20.0 °C(Predicted)
• 密度：
  1.504±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P264,P270,P301+P312,P330
• 危险性描述：
  H302,H315,H320,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 3-bromo-4-fluorobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 3-bromo-4-fluorobenzoate
CAS number: 23233-33-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8BrFO2
Molecular weight: 247.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴-4-氟苯甲酸乙酯 在 palladium on activated charcoal 乙酸铵 、 氢气 、 sodium hydride 、 溶剂黄146 、 二甲基亚砜 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 生成 4-[2-(3-Bromo-4-fluoro-phenyl)-5-piperidin-4-yl-1H-pyrrol-3-yl]-pyridine
  参考文献：
  名称：

  Synthesis and SAR of 2,3-diarylpyrrole inhibitors of parasite cGMP-dependent protein kinase as novel anticoccidial agents

  摘要：

  Several analogs of 2,3-diaryl pyrroles were synthesized and evaluated as inhibitors of Eimeria tenella cGMP-dependent protein kinase and in. in vivo anticoccidial assays. A 4-fluorophenyl group enhances both in vitro and in Vivo activities. The most potent analogs are the-5-(N-methyl, N-ethyl, and N-methylazetidine methyl) piperidyl derivatives 12, 23, and 34. These compounds have a broad spectrum of activity. Based on the in vivo efficacy and cost of synthesis, the N-ethyl analog 23 was chosen as a novel anticoccidial agent for a field trial. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.060
• 作为产物：
  描述：

  乙醇 、 3-溴-4-氟苯甲酸 在 硫酸 作用下， 反应 6.0h， 以91%的产率得到3-溴-4-氟苯甲酸乙酯
  参考文献：
  名称：

  通过钯催化的分子内环化反应轻松合成吲哚[3,2,1- jk ]咔唑

  摘要：

  描述了一种新的高效合成吲哚[3,2,1- jk ]咔唑的方法，该方法通过钯催化的N-（2-溴芳基）咔唑的环化反应来实现。该反应涉及分子内CC键的形成，以及咔唑环上CX键和CH键的断裂。引入具有给电子基团或吸电子基团的N-芳基核上的取代基，并评估了用于环化的不同反应因子。

  DOI：

  10.1016/j.tetlet.2012.07.093

文献信息

• [EN] NOVEL HETEROARYL IMIDAZOLES AND HETEROARYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS<br/>[FR] NOUVEAUX HÉTÉROARYL-IMIDAZOLES ET HÉTÉROARYL-TRIAZOLES À TITRE DE MODULATEURS DE GAMMA-SÉCRÉTASE
  申请人：PFIZER

  公开号：WO2011048525A1

  公开（公告）日：2011-04-28

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I; (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药学上可接受的盐被披露，其中所述化合物具有如下式的结构；（I）如规范中定义的那样。相应的药物组合物、治疗方法、合成方法和中间体也被披露。
• COMPOUND HAVING 6-MEMBERED AROMATIC RING
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2253618A1

  公开（公告）日：2010-11-24

  An object of the present invention is to provide an agent for preventing or treating schizophrenia or the like, wherein the compound of the present invention has GPR52 agonist activity. [Means] A compound represented by the following formula (I) or salt thereof: wherein A represents -(CH2)n-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, or the like, X1, X2, X3, and X4 represent the same or different -CRx=, or -N=, Y represents -O-, -S-, -S(O)-, -S(O)2-, or NRy-, Z represents a bond, methylene, or ethylene, Ar1 represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and the like, Ar2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and the like, and which may be condensed with an optionally substituted five-to six-membered ring, and Ra, Rb, Rx, and Ry represent the same or different hydrogen atom, halogen atoms, or the like].

  本发明的一个目的是提供一种用于预防或治疗精神分裂症或类似疾病的药剂，其中本发明的化合物具有GPR52激动剂活性。[意味着]由以下式(I)表示的化合物或其盐：其中A代表-(CH2)n-CO-NRa-（n为0到3的整数）或-NRa-CO-，B代表氢原子，卤素原子，氰基，羟基等，X1，X2，X3和X4代表相同或不同的-CRx=或-N=，Y代表-O-，-S-，-S(O)-，-S(O)2-，或NRy-，Z代表键，亚甲基，或乙烯基，Ar1代表一个五至十元芳香环（除噻唑外），可以用一个或多个卤素原子、可选择的卤代C1-6烷基等取代基取代，Ar2代表一个五至六元芳香环，可以用一个或多个卤素原子、可选择的卤代C1-6烷基等取代基取代，可以与一个可选择的取代的五至六元环螯合，并且Ra、Rb、Rx和Ry代表相同或不同的氢原子、卤素原子等。
• Design and Synthesis of Highly Potent and Isoform Selective JNK3 Inhibitors: SAR Studies on Aminopyrazole Derivatives
  作者：Ke Zheng、Sarah Iqbal、Pamela Hernandez、HaJeung Park、Philip V. LoGrasso、Yangbo Feng

  DOI：10.1021/jm501256y

  日期：2014.12.11

  expressed primarily in the brain. Numerous reports have shown that inhibition of JNK3 is a promising strategy for treatment of neurodegeneration. The optimization of aminopyrazole-based JNK3 inhibitors with improved potency, isoform selectivity, and pharmacological properties by structure–activity relationship (SAR) studies utilizing biochemical and cell-based assays, and structure-based drug design is reported

  c-jun N末端激酶3（JNK3）主要在大脑中表达。大量报告表明，抑制JNK3是治疗神经退行性疾病的一种有前途的策略。据报道，通过利用生物化学和基于细胞的分析的结构-活性关系（SAR）研究以及基于结构的药物设计，优化了具有增强的效能，同工型选择性和药理特性的基于氨基吡唑的JNK3抑制剂。这些抑制剂具有对JNK1和p38α的高选择性，最小的细胞毒性，对6-OHDA诱导的线粒体膜电位耗散和ROS生成的有效抑制，以及静脉给药的良好药物代谢和药代动力学（DMPK）特性。26n已针对464种激酶进行了分析，结果发现该酶具有高选择性，仅能击中7种激酶，在10μM时抑制率> 80％。此外，26n显示出良好的溶解度，良好的大脑渗透能力和良好的DMPK特性。最后，在1.8Å处解析了与JNK3形成的26k晶体结构，以探索基于氨基吡唑的JNK3抑制剂的结合模式。
• AMIDE COMPOUND
  申请人：Setoh Masaki

  公开号：US20100041891A1

  公开（公告）日：2010-02-18

  A compound having GPR52 agonist activity or a salt thereof is provided. The compound can be provided as a preventive/therapeutic agent for schizophrenia or the like. The compound is represented by the following formula: wherein A represents —CONR a — or —NR a CO—, R a represents a hydrogen atom or the like, B represents a hydrogen atom or the like, a ring Cy1 represents a six-membered aromatic ring which may have one or more substituents in addition to a group represented by -A-B, a ring Cy2 represents a six-membered ring which may be substituted with a halogen atom or the like, a ring Cy3 represents a five- or six-membered ring which may have one or more substituents; X represents C 1-2 alkylene or the like, m represents an integer of 0 to 2, and a ring Cy4 represents a six-membered aromatic ring which may have one or more substituents.

  提供具有GPR52激动剂活性或其盐的化合物。该化合物可作为预防/治疗精神分裂症等疾病的药物。该化合物由以下公式表示：其中A代表—CONRa—或—NRaCO—，Ra代表氢原子或类似物质，B代表氢原子或类似物质，环Cy1代表一个六元芳香环，除了由-A-B表示的基团外，可能有一个或多个取代基，环Cy2代表一个六元环，可能被卤素原子或类似物质取代，环Cy3代表一个有一个或多个取代基的五元或六元环；X代表C1-2烷基或类似物质，m代表0到2之间的整数，环Cy4代表一个六元芳香环，可能有一个或多个取代基。
• Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators
  申请人：am Ende Christopher William

  公开号：US20120202787A1

  公开（公告）日：2012-08-09

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I; as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本文披露了化合物及其药学上可接受的盐，其中化合物具有I式结构，如规范中定义。还披露了相应的制药组合物、治疗方法、合成方法和中间体。